


The Global Parkinson's Genetics Program (GP2)

NASEM Forum on Neuroscience & Nervous System Disorders From Molecular Insights to Patient Stratification for Neurological and Psychiatric Disorders: A Workshop October 5, 2021

Ekemini Riley, PhD ASAP Managing Director



GP2 is an ASAP Resource Project



WWW.PARKINSONSROADMAP.ORG WWW.GP2.ORG

ASAP Mission

To accelerate the pace of discovery and inform the path to a cure for Parkinson's disease through collaboration, research-enabling resources, and data sharing.

Implementation Partner

ASAP is leveraging the grantmaking infrastructure and clinical coordination expertise of The Michael J. Fox Foundation to implement its programs.



Filling Gaps within the Research Ecosystem



95%

of large-scale genetic discovery work in PD is performed in populations of Northern European Ancestry.

GP2 aims to fill this gap and provide a blueprint for how this can be done.



To dramatically expand our understanding of the genetic basis of PD and to make that knowledge globally relevant.

GP2 is on pace to genotype 150,000+ ancestrally diverse volunteers worldwide.



- Intentional engagement with various communities
- 2 Capacity building

Key GP2 Structural Priorities: Diversity in Research and Researchers Collaboration & Cooperation



GP2 Mission & Path Forward

To dramatically expand our understanding of the genetic basis of PD and to make that knowledge globally relevant

SCIENTIFIC OUTCOMES



Complex Disease

dramatic expansion of known genetic risk

whole genome genotyping of >150.000 individuals

Doubling in known risk loci Improved PRS for prediction and modeling

Mutation carriers identified (every known assayable NDD mutation)

Genetic basis of onset, progression

Genetic modifiers of *LRRK2*, *GBA* Samples, tissues, cells available



Monogenic Disease

enabling, accelerating, improving mutation discovery

whole genome sequencing of >10,000 individuals

Rapid identification of new causal genes for PD Validation Resource for new

Long read sequencing resource Exploration of SV and repeats in

disease causation
Samples, tissues, cells, with known genetic architecture



Global Disease

making our understanding of genetics globally relevant

ancestral diversity in all genetic analyses

Black Americans, Africa, South and Central America, East Asia, Central Asia

Mapping heterogeneity

Accelerated fine mapping to reveal effector gene and mechanism Identification of populations enriched for genetic factors

Diverse patient samples, tissues, cells with known genetic architecture

STRUCTURAL PRIORITIES

Democratization of Data

Collaboration and Cooperation

Safe, Responsible Data Sharing

Diversity in Research and Researchers

Transparency & Reproducibility

Foundational. Actionable Resource Production



Laying the Foundation with Diverse, Distributed Leadership

Steering Committee

Andrew Singleton | Cornelis Blauwendraat | Tatiana Foroud | Alastair Noyce | Christine Klein | Enza Maria Valente | Peter Heutink | Huw Morris | Mike Nalls | Ignacio Mata | Nicholas Wood | Alexis Brice | Thomas Gasser | Nigel Williams | Brian Fiske | Bradford Casey | Alyssa Reimer | Ekemini Riley | Rejko Kruger | Ken Marek | Mie Rizig | Manu Sharma | Kin Mok

Operations and Compliance

Tatiana Foroud | Alyssa Reimer | Claire Wegel | Justin Solle | Thomas Gasser | Schuyler Fox | Christine Klein | Enza Maria Valente | Njideka Okubadejo | Ignacio Mata | Mary Makarious | Hampton Leonard | Mie Rizig | Miriam Peleman | Niccolo Mencacci | Huw Morris

Training and Networking

Alastair Noyce | Sara Bandres-Ciga | Sumit Dey | Claire Bale | Maggie Kuhl | Hampton Leonard | Patrick Lewis |
Benjamin Stecher | Simon Stott | Sabina Adams | Alejandro Carrasco

Monogenic Disease (MD) Hub

Christine Klein | Niccolo Mencacci | Katja Lohmann | Kishore Raj Kumar | Peter Heutink | Enza Maria Valente | Shen-Yang Lim

MG Sample Prioritization

Christine Klein | Kishore Kuma

MG Data Analyses

Peter Heutink | Zih-Hua Fang

MG Portal Development

nza Maria Valente | Shen-Yang Lim

Complex Disease (CD) Hub

Andrew Singleton | Cornelis Blauwendraat | Caroline Pantazis | Dena Hernandez | Ruqaya Murtadha

CD Cohort Integration

Huw Morris | Hirotaka Iwaki | Manuela Tan

CD Data Analyses

Mike Nalls | Hampton Leonard | Sara Bandres-Ciga | Cornelis Blauwendraat | Jean-Christophe Corvol | Ignacio Mata | Hirotaka Iwaki | Jeff Kim | Mary Makarious | Yeajin Song | Dan Vitale | Nigel Williams

Underrepresented Populations

Ignacio Mata | Artur F. Schumacher-Schuh | Shen-Yang Lim | Olaitan Okunoye | Sara Bandres-Ciga | Peter Heutink | Hirotaka lwaki | Rejko Kruger | Kin Mok | Alastair Noyce | Njideka Okubadejo | Mie Rizig | Manu Sharma | Joshua Shulman | Bernadette Siddiqi

Data and Code Dissemination

Bradford Casey | Mary Makarious | Jeff Kim

Project Proposal, Approval, and Execution

John Hardy | Njideka Okubadejo | Mario Cornejo Olivas | Huifang Shang | Ruqaya Murtadha | Dena Hernandez | Sara Bandres Ciga | Yeajin Song | Thomas Gasser



Time & Scale

\$35M committed over Y3: Production phase Fully operational Critical assessment on progress, highlight additional opportunities Y1: Start-up phase Compliance, Data-sharing, Minimal clinical dataset criteria, NeuroPlus array, Y5: Wind down Policies All cohorts/samples on boarded; genetic data production complete, analyses to We are ● wrap up this phase of the project here Year 1 Year 2 Year 3 Year 4 Year 5 ♦Y2: Production phase begins Data generation, creation of data platform, creation of monogenic portal Y4: Production phase Fully operational



Intentional Engagement



Intentional engagement through strategic partnerships...

↑ Y1: Start-up phase

Compliance, Data-sharing, Minimal clinical dataset criteria, NeuroPlus array, Policies

We are here

Year 1

Year 2

Y2: Production phase begins

Data generation, creation of data platform, creation of monogenic portal



Shared training materials, outreach to cohorts and underserved populations, joint meetings, free membership to GP2, access to scales, translation of scales



Data access through a controlled environment, user access to include browsing of results and in situ analysis of data to democratize analysis



Creation of a global diversity array with neurodegenerative disease content



Collaboration on the PD GENEration study, that aims to provide genetic results and counseling to 10,000 PD patients



Generation of genotype, whole genome sequencing, and long read sequencing data on the most well-characterized PD cohort in the world



Collaborative partnerships with existing international consortia in the PD genetics field





...leading to the launch of programs & commitments to contribute cohorts and samples globally



Understanding Genetic Implications of the Black and African American Connections to Parkinson's Disease Study (BLAAC PD)

By Sara Bandres-Ciga, Justin C. Solle, Alyssa Reimer, and Bernadette Siddiqi | GP2 Values, GP2 Values | July 23, 2021



In partnership with

CARE: Community Access,
Recruitment, and Engagement



Increasing Underrepresented Hispanic Participation in Parkinson's and Genomic Research Through the LARGE-PD Study

By Ignacio Fernandez Mata, Philippe Salles, Shilpa Rao, Miguel Inca Martinez, Nicolas Gutierrez, and Thiago Peixoto | Uncategorized | September 27, 2021





Considering Access from the End User Perspective

ASAP presents GP2.org now available in:

آراع English 简体中文 Español

日本語 Deutsch Français

Expanding global reach with language accessibility




Capacity Building



Building global will and capacity

ACCESS

Access for learners worldwide through online learning platform.



training.gp2.org

Join 400+ learners | 4 courses

TRAINING

Fund genetics MSc & PhD programs for clinicians and researchers in low-to-middle income countries.



Trainees announced next week!

Building diverse researcher & clinician pool

INFRASTRUCTURE

Contribute to infrastructure development to enable current & future research.



Helped to fund the construction of the first DNA Biobank in Peru!



An Actionable Blueprint





Journal of Parkinson's Disease 11 (2021) 905–908 DOI 10.3233/JPD-212593 IOS Press

Michael J. Fox Foundation – Position Paper

A Call to Action: Promoting Diversity, Equity, and Inclusion in Parkinson's Research and Care

Bernadette Siddiqi* and Andrew Koemeter-Cox The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA



- Identifying barriers and solutions to research participation
- Funding inclusive research with greater participant diversity
- Building a clinician/researcher workforce committed to health equity
- Supporting a more holistic understanding of PD



Want More Information?

- GP2 website: www.gp2.org
- GP2 blog series: www.gp2.org/blog
 - 15 blog posts now available!
- GP2 Programmatic Overview
 - Movement Disorders, 2021. (PMID: 33513272)
- Questions? Feel free to reach out to:
 - Ekemini Riley, ASAP Managing Director:
 eriley@parkinsonsroadmap.org
 - Andy Singleton, GP2 Principal Investigator: <u>singleta@mail.nih.gov</u>

